Abstract:Abstract Background CARs are simulated receptors containing an extracellular single-chain variable fragment (scFv), a transmembrane domain, as well as an intracellular region of immunoreceptor tyrosine-based activation motifs (ITAMs) in association with a co-stimulatory signal. Main body Chimeric antigen receptor (CAR) T cells are genetically engineered T cells to express a receptor for the recognition of the particular surface marker that has given rise to advances in the treatment of blood disorders. The CAR T cells obtain supra-physiological properties and conduct as “living drugs” presenting both immediate and steady effects after expression in T cells surface. But, their efficacy in solid tumor treatment has not yet been supported. The pivotal challenges in the field of solid tumor CAR T cell therapy can be summarized in three major parts: recognition, trafficking, and surviving in the tumor. On the other hand, the immunosuppressive tumor microenvironment (TME) interferes with T cell activity in terms of differentiation and exhaustion, and as a result of the combined use of CARs and checkpoint blockade, as well as the suppression of other inhibitor factors in the microenvironment, very promising results were obtained from the reduction of T cell exhaustion. Conclusion Nowadays, identifying and defeating the mechanisms associated with CAR T cell dysfunction is crucial to establish CAR T cells that can proliferate and lyse tumor cells severely. In this review, we discuss the CAR signaling and efficacy T in solid tumors and evaluate the most significant barriers in this process and describe the most novel therapeutic methods aiming to the acquirement of the promising therapeutic outcome in non-hematologic malignancies.

Comprehensive clinical evaluation of CAR-T cell immunotherapy for solid tumors: a path moving forward or a dead end?

Advances and Hurdles in CAR T Cell Immune Therapy for Solid Tumors

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

Prospects and challenges for use of CAR T cell therapies in solid tumors

Bright future or blind alley? CAR-T cell therapy for solid tumors

Overcoming efficiency limitations of CAR-T cell therapy in antigen-heterogeneous solid tumors

CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances

CAR T-cell Therapy: A New Era in Cancer Immunotherapy

CAR-T cells: the long and winding road to solid tumors

CAR T cell therapy: Current limitations and advancements in treating solid tumors

Hurdles to breakthrough in CAR T cell therapy of solid tumors

Current Clinical Application of the CAR-T Cell Therapy

CAR T cells in solid tumors: challenges and opportunities

Current Progress in CAR-T Cell Therapy for Solid Tumors

Advancing CAR T-Cell Therapy for Solid Tumors: Lessons Learned from Lymphoma Treatment

Advanced Strategies of CAR-T Cell Therapy in Solid Tumors and Hematological Malignancies

CAR T cells in solid tumors and metastasis: paving the way forward

A long way to the battlefront: CAR T cell therapy against solid cancers.

CAR T-cell immunotherapy: The path from the by-road to the freeway?

Chimeric-antigen receptor T (CAR-T) cell therapy for solid tumors: challenges and opportunities.

CAR-T: What Is Next?